Operational update on the diabetes vaccine Diamyd® and recombinant GAD

Diamyd Medical hereby provides an update on its operations, including the intralymphatic trials with Diamyd®  and the GAD production.Clinical trials with intralymphatic administration of Diamyd®As previously announced, there is a great interest in the DIAGNODE-2 trial, where the diabetes vaccine Diamyd® is administered directly into the lymph node, and it is further increasing, according to recent information from the clinics. As of March 1, 33 patients had been evaluated (screened) if they could be included in the trial, of which 24 were screened in February only. The time from when a